CONSONUS PHARMACY

COVID-19 Vaccine Operation Warp Speed (OWS) FAQ

November 12. 2020

Attention: Home Office Leaders, Administrators, Directors' of Nursing

As your trusted pharmacy partner, we want to address the most common questions that our customers have had after navigating the sign-up process through the pharmacy partnership portals. We will continue to update you as we move through this dynamic time together.

Q: Am I guaranteed that the pharmacy partner that I selected, will be the one to provide the vaccine?

A: No. Ultimately the Centers for Disease Control (CDC) will assign the pharmacy that will distribute the vaccine. We anticipate pharmacies will be notified soon of the facilities that they will be responsible for. It is unclear at this time if the CDC will allow this to be done by existing relationships or if it will be done by location given the storage sensitivity of the product. As more information becomes available, we will keep you posted.

Q: Can I change my pharmacy partner after the registration deadline of 11.6.2020?

A: After the form closes, no changes can be made via the National Healthcare Safety Network (NHSN) or the online form. The facility will have to coordinate directly with the pharmacy provider selected regarding vaccination supply and services or contact the CDC Pharmacy Partnership Team at eocevent494@cdc.gov.

Q: Do I need to stock up on supplies to give the vaccine now that I am signed up?

A: An ancillary supply kit will be included with the vaccine. Each kit will include: syringe, needle (appropriate for population), alcohol prep pad, COVID-19 vaccination record card for each recipient. The kit will also include limited supplies of personal protective equipment (PPE), including surgical masks and face shields for vaccinators. NOT included in the kit will be sharps containers, gloves and bandages.

Q: When will we get clinical information on the vaccine, such as efficacy, side effects, contraindications, etc.?

A: Pfizer and BioNTech's investigational vaccine showed successful preliminary data from phase 1 and 2 studies in July. Recent results of an interim analysis from the phase 3 COVID-19 vaccine trial showed an efficacy rate above 90% at 7 days after the second dose, meaning that protection is achieved 28 days after initiation of the 2-dose vaccination schedule. This is very encouraging!

To date no serious safety concerns have been reported. Local adverse events in phase 1 and 2 trials included injection-site pain, redness and swelling. In the ongoing phase 3 trial, the manufacturer has reported mostly mild to moderate adverse reactions (fatigue and headache have been the most common).

More information on safety and efficacy is expected in the upcoming weeks as the vaccine trial continues through the final analysis.

Q: What steps are being taken to ensure the COVID vaccine is going to be safe and effective?

A: In addition to the FDAs rigorous scientific and regulatory processes in place to ensure the safety, effectiveness and quality of vaccines, the Western States have joined a COVID-19 Scientific Safety Review Workgroup to independently review the safety and efficacy of any vaccine approved before distribution in the states.